Aquestive Therapeutics names new senior vice president, general counsel
12 September 2018 -

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercialising products for unmet medical needs, announced on Tuesday that it has appointed Lori J. Braender, Esq as its new senior vice president, general counsel, effective 10 September 2018.

Braender is joining Aquestive from a 35-year career at Day Pitney LLP, where she was most recently chair of the Life Sciences Practice Group. In that role, she specialised in advising clients in pharmaceutical, biotechnology, medical device companies, hospitals and healthcare institutions on regulatory requirements, contractual arrangements, and other business considerations connected with life science and healthcare transactions.

Keith J. Kendall, chief executive officer of Aquestive Therapeutics, stated: "We are pleased to welcome Lori. With her knowledge and familiarity of the company, and the depth of her professional experience, Lori will be an important part of the leadership of Aquestive."